source
- FDA says trial manipulation undermines approval of ChemoCentryx's Tavneos, now owned by AmgenThe U.S. Food and Drug Administration has announced that it believes the pivotal trial supporting the approval of Tavneos was manipulated. The agency says ChemoCentryx, which was acquired by Amgen…
- Eli Lilly partners with AI startup Profluent to develop next-generation gene editorsEli Lilly announced a collaboration with AI-focused biotech Profluent to create advanced gene-editing tools that could insert whole genes into patients. The partnership is intended to move beyond…